Source:http://linkedlifedata.com/resource/pubmed/id/10755201
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2000-8-11
|
pubmed:abstractText |
The QUO VADIS (the effects of QUinapril On Vascular Ace and Determinants of ISchemia) study was a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of long-term angiotensin-converting enzyme (ACE) inhibition on angiotensin II formation in human vasculature. Patients (n = 187) scheduled for coronary artery bypass surgery used study medication 27 +/- 1 days before surgery. Segments of internal mammary arteries were exposed to increasing doses (0.1 nM-1 microM) of angiotensin I and II in organ baths. The rate of local angiotensin II formation is a function of the reciprocal of the difference between the pEC50's of the dose response curves to angiotensin I and II (-log/mol) and of the area between the curves (units). Quinapril (40 mg) and captopril (3 x 50 mg) similarly and significantly reduced mean blood pressure compared with placebo (p = 0.04). Difference between pEC50's was 0.90 +/- 0.08 in quinapril patients compared with 0.60 +/- 0.08 for placebo (p = 0.01); the area between curves was 91 +/- 8 for quinapril patients compared with 67 +/- 8 for placebo (p = 0.03). Angiotensin II formation was decreased to a lesser extent with captopril and was not statistically different from placebo (p = 0.3); the difference between pEC50's was 0.83 +/- 0.15; the area between curves was 84 +/- 12. This is the first randomized study to demonstrate that long-term oral treatment with an ACE inhibitor reduces vascular angiotensin II formation in humans.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0920-3206
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
55-60
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10755201-Administration, Oral,
pubmed-meshheading:10755201-Angiotensin I,
pubmed-meshheading:10755201-Angiotensin II,
pubmed-meshheading:10755201-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:10755201-Blood Pressure,
pubmed-meshheading:10755201-Cardiovascular Diseases,
pubmed-meshheading:10755201-Coronary Artery Bypass,
pubmed-meshheading:10755201-Double-Blind Method,
pubmed-meshheading:10755201-Female,
pubmed-meshheading:10755201-Humans,
pubmed-meshheading:10755201-Male,
pubmed-meshheading:10755201-Middle Aged,
pubmed-meshheading:10755201-Prospective Studies,
pubmed-meshheading:10755201-Renin-Angiotensin System,
pubmed-meshheading:10755201-Single-Blind Method
|
pubmed:year |
2000
|
pubmed:articleTitle |
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators.
|
pubmed:affiliation |
Department of Clinical Pharmacology, University of Groningen, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|